|
May 14
|
BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology
|
|
May 13
|
ORLADEYO® (berotralstat) Approved in Mexico
|
|
May 9
|
BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)
|
|
May 9
|
Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its First-Quarter Results
|
|
May 7
|
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q1 2024 Earnings Call Transcript
|
|
May 7
|
BioCryst Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
|
|
May 7
|
BioCryst Pharmaceuticals Inc (BCRX) Q1 2024 Earnings Call Transcript Highlights: Key Financial ...
|
|
May 7
|
Q1 2024 BioCryst Pharmaceuticals Inc Earnings Call
|
|
May 6
|
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
|
|
May 6
|
BioCryst Pharmaceuticals 'Fantastic' Q1 Earnings Rides On Outstanding Orladeyo Performance
|
|
May 6
|
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
|
|
May 6
|
BioCryst Pharmaceuticals Reports Strong Q1 2024 Results, Exceeding Analyst Revenue Forecasts
|
|
May 6
|
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 6
|
BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 30
|
Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know
|
|
Apr 29
|
BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
|
|
Apr 22
|
With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing
|
|
Apr 22
|
BioCryst to Report First Quarter 2024 Financial Results on May 6
|
|
Apr 17
|
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
|
|
Apr 10
|
12 Best Depressed Stocks To Buy in 2024
|